Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Approval for Pivastatin Calcium API
Category:
发布时间:2022-05-14
【概要描述】
Recently, the pitavastatin calcium API developed and submitted for approval by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been approved by the National Medical Products Administration, enabling its official use in marketed pharmaceutical formulations.
Recently, the pitavastatin calcium API developed and submitted for approval by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group has been approved by the National Medical Products Administration and may now be officially used in marketed pharmaceutical formulations.
It is reported that pitavastatin calcium preparations are primarily used in clinical practice for the treatment of hypercholesterolemia and familial hypercholesterolemia.
Keywords:
Recommended News
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091